Y. Tasaki

Effectiveness of continuous monitoring by activity tracker of patients undergoing chemotherapy for urothelial carcinoma.

Keitaro Iida, T. Naiki, S. Nozaki, 2020, Cancer treatment and research communications.

Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma

Keitaro Iida, T. Naiki, S. Nozaki, 2020, Oncology.

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma

T. Naiki, T. Etani, S. Hamamoto, 2024, Journal of Clinical Medicine.

Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma

T. Yasui, S. Hamamoto, Y. Tasaki, 2024, Translational Andrology and Urology.

Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study

T. Naiki, H. Komatsu, T. Shimura, 2023, Cancer medicine.

Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma

T. Naiki, T. Etani, N. Kawai, 2023, International journal of urology : official journal of the Japanese Urological Association.

Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma

Yoko Furukawa-Hibi, T. Naiki, T. Etani, 2023, International journal of urology : official journal of the Japanese Urological Association.

Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer

T. Noda, K. Kataoka, Y. Kondo, 2021, Cancer Research.

Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis

T. Naiki, T. Nagai, T. Etani, 2020, Oncology.